New CE Marked Test Simultaneously Detects Up To 95% of Gastrointestinal Infections in Under Five Hours
AUSTIN, Texas and MILAN, May 5, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that it has received CE marking for its new xTAG Gastrointestinal Pathogen Panel (GPP).This innovative assay is the first test of its kind to help identify up to 95 percent of the disease causing pathogens in a single test. It delivers the highest number of relevant answers per sample in time to positively affect patient care.
Infectious gastroenteritis strikes more than two billion times globally each year and is a leading cause of child morbidity and mortality worldwide(1). In the European Union, 207 million cases of diarrhea occur which lead to greater than 200,000 hospitalizations and over 1,000 deaths every year, inflicting a significant toll on the health care system(2).
As the most comprehensive test available to diagnose gastrointestinal infections, xTAG GPP simultaneously detects fifteen of the most common disease-causing pathogens, including viral, bacterial and parasitic infections, such as E. coli, Campylobacter, Salmonella and C. difficile. Providing accurate and timely identification of causative pathogens ultimately leads to improved health care outcomes and reduced costs. Additionally, the fast turn-around time and simultaneous testing on a single sample enable laboratories to better utilize their time and resources.
"The difficulty associated with diagnosing gastrointestinal infections can be frustrating for both physicians and patients when lab tests are inconclusive and effective treatment cannot be initiated, causing delays in therapy and increasing the cost of health care," said Jeremy Bridge-Cook, Ph.D., senior vice president of Luminex's assay group. "xTAG